CJC-1295 with DAC
CJC-1295 with DAC (Drug Affinity Complex) is a robustly modified Growth Hormone Releasing Hormone (GHRH) analog engineered to overcome the exceptionally short half-lives of traditional secretagogues. By utilizing a highly unique biochemical tether that binds to endogenous blood albumin, this peptide continuously elevates basal Growth Hormone and IGF-1 levels for over a week from a single injection. It is structurally designed to augment massive systemic recovery, joint health, and slow wave sleep architecture via persistent, elevated hormonal output.
Quick Stats
Scientific Data
Mechanism of Action
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). The DAC modification binds to albumin in the bloodstream, extending the half-life from 30 minutes to 5.8-8.1 days. This creates sustained, elevated growth hormone release from pituitary somatotroph cells.
Unlike direct GH administration, CJC-1295 DAC preserves the natural pulsatile pattern of GH secretion (amplifying pulse amplitude rather than creating a flat, non-physiological elevation). This results in elevated IGF-1 levels for up to 6-14 days after a single injection. Clinical studies showed a 2-10× increase in GH concentrations and sustained IGF-1 elevation.
Source: PMID: 16352683
Background & History
CJC-1295 with DAC was developed by ConjuChem Biotechnologies (Canada) in the early 2000s as a long-acting GHRH analog. The Drug Affinity Complex (DAC) technology covalently binds the peptide to endogenous albumin via a maleimide linker, dramatically extending half-life. A 2006 Phase II clinical trial (Walker et al., Journal of Clinical Endocrinology & Metabolism) showed 2–10× GH elevation lasting 6–14 days post-injection, with sustained IGF-1 elevation — validating its once-weekly dosing potential.
Research Use Cases
- ✓GH optimization for body composition (muscle gain, fat loss)
- ✓Age-related GH decline (somatopause) management
- ✓Recovery enhancement via sustained IGF-1 elevation
- ✓Convenient once-weekly GH secretagogue protocol
- ✓Anti-aging and sleep quality improvement
Dosing Protocol
| Typical Dose | 1000-2000 mcg/week |
| Frequency | 1-2× weekly |
| Half-Life | 5.8-8.1 days |
| Common Vial Sizes | 2 mg, 5 mg |
Dosing Protocols
Standard Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 1000–2000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 771 mcg | 1157 mcg | 1543 mcg |
| 140 lb(63 kg) | 900 mcg | 1350 mcg | 1800 mcg |
| 160 lb(73 kg) | 1043 mcg | 1564 mcg | 2086 mcg |
| 180 lb(82 kg) | 1171 mcg | 1757 mcg | 2343 mcg |
| 200 lb(91 kg) | 1300 mcg | 1950 mcg | 2600 mcg |
| 220 lb(100 kg) | 1429 mcg | 2143 mcg | 2857 mcg |
| 250 lb(113 kg) | 1614 mcg | 2421 mcg | 3229 mcg |
💉 For exact syringe units based on your vial concentration, use the CJC-1295 with DAC Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Anti-Aging / Longevity
ModerateSustained GH/IGF-1 elevation without daily injections — favorable for long-term protocols.
Body Composition
ModerateLean mass support and fat reduction with weekly dosing convenience.
Reconstitution Example
Safety & Considerations
Research peptide — not FDA-approved. May cause water retention, numbness/tingling in extremities, and headache. Should not be used by individuals with active cancer due to GH/IGF-1 elevation. Growth hormone secretagogues may affect blood glucose levels.
Regulatory & Legal Status
Competitive athletes subject to anti-doping controls should not use CJC-1295 with DAC.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
GH secretagogues elevate blood glucose — monitor in pre-diabetic or insulin-resistant individuals. May cause carpal tunnel syndrome at high IGF-1 levels. Contraindicated with active cancer. Thyroid hormones affect GH sensitivity; ensure thyroid function is optimized.
Synergies & Common Stacks
GHRH + GHRP synergy: CJC-1295 DAC provides sustained background GH elevation; Ipamorelin adds clean discrete pulses. Together they produce more GH than either alone without cortisol/prolactin elevation.
Both drive GH/IGF-1 elevation via different mechanisms (GHRH vs ghrelin pathway). Stacking amplifies total GH output but requires careful monitoring for IGF-1 excess.
CJC-1295 with DAC vs. CJC-1295 (No DAC)
| Attribute | CJC-1295 with DAC | CJC-1295 (No DAC) |
|---|---|---|
| DAC Modification | Drug Affinity Complex (DAC) attached | No DAC — plain modified GHRH |
| Half-Life | 5.8–8.1 days (once or twice weekly) | ~30 minutes (1–3× daily required) |
| GH Pattern | Sustained non-pulsatile bleed | Sharp, natural-mimicking pulses |
| Stacking | Typically used solo or with GHRP | Best paired with Ipamorelin (gold standard) |
| Convenience | Maximum — 1–2×/week dosing | Requires 1–3 daily injections |
| IGF-1 Concerns | Higher IGF-1 elevation (sustained) | More physiological IGF-1 profile |
Verdict: CJC-1295 DAC wins for convenience (twice-weekly dosing); CJC-1295 No DAC wins for physiological GH pulse preservation. The No DAC + Ipamorelin stack is preferred by most protocols for mimicking natural GH rhythms and avoiding chronically elevated IGF-1.
Dosing Quick Reference
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?▼
How do I dose CJC-1295 DAC?▼
When should I inject CJC-1295 DAC?▼
References
- Ionescu & Frohman “"CJC-1295, a long-acting growth hormone-releasing hormone analog".” Journal of Clinical Endocrinology & Metabolism (2006). PMID: 16822818
📚 Related Articles
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code